


Key Takeaways: Identifying and Managing Patients Without Cirrhosis

(Video 3.0)

HCV.com



Who is a patient without cirrhosis?

- Patients without cirrhosis may have some liver damage, but have not progressed to more advanced liver disease^{1,2}
- Patients without cirrhosis very rarely display any symptoms^{1,2}

Patients with fibrosis stage F3 or higher are at increased risk of developing complications and are recommended for frequent follow-up³


Ongoing imaging surveillance for liver cancer and gastroesophageal varices is recommended for these patients³



The degree of hepatic fibrosis is key to determining the initial and follow-up management of patients³

Fibrosis staging

No cirrhosis



Non-invasive assessments of fibrosis



Fibrosis-4 (FIB-4)

A calculation for estimating the amount of scarring in the liver⁴⁻⁶



FibroSure®

A biomarker test that assesses liver fibrosis – values correspond to METAVIR scoring from liver biopsy (F0–F4)^{4,6,7}



Aspartate aminotransferase to platelet ratio (APRI)

A calculation that uses platelet count and AST to estimate the likelihood of significant fibrosis or cirrhosis^{4,6,7}



FibroScan®

Transient elastography to assess liver stiffness^{4,8-10}

FibroSure® is a registered trademark of Laboratory Corporation of America Holdings. FibroScan® is a registered trademark of Echosens Company.

AASLD-IDSA HCV treatment guidelines recommend using the simplified treatment pathway for treatment-naïve patients without cirrhosis³

Patients with advanced fibrosis may require referral to specialist treatment, including surveillance every 6 months for liver cancer³



References

1. Asselah T, et al. *Gut* 2009;58:846–858
 2. Poynard T, et al. *Semin Liver Dis* 2000;20:47–55
 3. AASLD and IDSA. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Last updated May 2020. <http://www.hcvguidelines.org>. Accessed July 2020
 4. Ipsos Healthcare HCV Monitor, 2017, New York, NY: Ipsos in North America
 5. Sterling RK, et al. *Hepatology* 2006;43:1317–1325
 6. Chou R, Wasson N. *Ann Intern Med* 2013;158:807–820
 7. Lin ZH, et al. *Hepatology* 2011;53:726–736
 8. Hepatitis C Online. Evaluation and Prognosis of Patients with Cirrhosis. <https://www.hepatitisc.uw.edu/go/evaluation-staging-monitoring/evaluation-prognosis-cirrhosis/core-concept/all>. Accessed September 2020
 9. Patel K, et al. *World J Gastroenterol* 2011;17:4581–4589
 10. Castera L, et al. *Gastroenterology* 2005;128:343–350
- ABBV-US-00238-MC, V1, October 2020

abbvie
US Medical Affairs